Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Testicular Seminoma
• MONDO ID: (if available)
• Category: Germ Cell Neoplasm

Research Objectives

Please provide a comprehensive research report on Testicular Seminoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Testicular Seminoma — Disease Characteristics Research Report (2023–2024-focused)

Executive summary

Testicular seminoma is a common histologic subtype of testicular germ cell tumor (TGCT) that typically affects adolescents and young-to-middle-aged adult men, is often diagnosed at early stage, and has excellent cure rates with orchiectomy and risk-adapted adjuvant management. Key 2023–2024 advances include: (i) higher-resolution genomic maps from whole-genome sequencing (WGS) that emphasize recurrent 12p copy-number gains (including KRAS-region 12p) and immune-evasion mechanisms (HLA loss) with seminoma enrichment, (ii) single-cell/spatial atlases describing immune-cell heterogeneity and exhaustion features in seminoma microenvironments, and (iii) prospective clinical validation of serum microRNA-371a-3p (M371/miR-371a-3p) for relapse detection and for assessing viable tumor in specific clinical contexts, with performance characteristics that exceed traditional serum tumor markers. (leathlobhair2024genomiclandscapeof pages 1-2, thor2024mir371a3ppredictingviable pages 1-2, islam2024tcellsin pages 1-2, belge2024detectionofrecurrence pages 1-2)

1. Disease information

1.1 Definition and current understanding

Testicular germ cell tumors (TGCTs) are categorized into seminoma and nonseminomatous germ cell tumors (NSGCT). Seminoma is generally considered to arise from germ cell neoplasia in situ (GCNIS) and is characterized by a developmental-arrest phenotype resembling primordial germ cells/gonocytes. (lu2023singlecellmultiomicsanalysis pages 1-2, sykes2024currentandevolving pages 1-2)

Primary abstract quote (single-cell atlas, 2023): - “Seminoma is the most common malignant solid tumor in 14 to 44 year-old men.” (lu2023singlecellmultiomicsanalysis pages 1-2)

1.2 Key identifiers (ontology/coding)

The tool-accessible evidence retrieved for this report does not contain authoritative crosswalk tables for ICD-10/ICD-11, MeSH, OMIM, Orphanet, or a seminoma-specific MONDO identifier. Consequently, these identifiers cannot be populated with citation-grade support from the current evidence set.

MONDO (partial, available in OpenTargets context): OpenTargets returned MONDO_0003510 for “malignant testicular germ cell tumor” (broader than seminoma). (OpenTargets Search: testicular seminoma)

1.3 Synonyms / alternative names

The retrieved evidence uses primarily: - “testicular seminoma” (leathlobhair2024genomiclandscapeof pages 1-2) - “seminoma” (lu2023singlecellmultiomicsanalysis pages 1-2) - “seminomatous germ cell tumor” (fazekas2024earlydetectionand pages 4-7)

1.4 Evidence source type

The information below is derived from: - Aggregated disease-level resources (narrative review and guideline-style review; registry-like incidence statements) (sykes2024currentandevolving pages 1-2) - Primary human tumor studies (WGS; single-cell/spatial profiling; prospective biomarker validation cohorts) (belge2024detectionofrecurrence pages 1-2, lu2023singlecellmultiomicsanalysis pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2)

2. Etiology

2.1 Disease causal factors (mechanistic)

A central mechanistic concept is that TGCTs (including seminoma) reflect failure to control the latent developmental potential of the fetal germ cell lineage, followed by later progression under hormonal and genetic influences.

Primary abstract quote (WGS, 2024): - “Unlike most other cancers, TGCTs are rarely caused solely by somatic driver mutations, but arise from failure to control the latent developmental potential of their cell-of-origin, a foetal germ cell, resulting in its reprogramming.” (leathlobhair2024genomiclandscapeof pages 1-2)

2.2 Risk factors

The current evidence set includes disease-level epidemiologic and etiologic framing (GCNIS origin, immune infiltration) but is limited on seminoma-specific quantitative risk factor estimates.

Cryptorchidism is referenced as an established association with testicular cancer in recent literature retrieved, and a 2024 review notes a meta-analysis estimate of increased testicular cancer risk in congenital cryptorchidism (not seminoma-specific in the retrieved excerpt). (OpenTargets Search: testicular seminoma)

Neurodevelopmental disorders (NDDs): A nested case–control study reports a specific association with seminoma. - Abstract quote: “History of a neurodevelopmental disorder … was associated with an increased risk of seminoma (OR: 1.54; 1.09–2.19).” (OpenTargets Search: testicular seminoma)

Male infertility is discussed in retrieved review literature as part of a shared etiologic framework (testicular dysgenesis syndrome concept), but quantitative seminoma-specific effect sizes were not extractable from the provided evidence snippets in this run. (OpenTargets Search: testicular seminoma)

2.3 Protective factors

No protective genetic or environmental factors with extractable quantitative support were identified in the gathered evidence.

2.4 Gene–environment interactions

No explicit GxE interaction results were extractable from the current evidence set.

3. Phenotypes (clinical presentation)

3.1 Typical presentation and clinical features

Seminoma typically presents as a testicular mass; clinically it often has normal AFP (pure seminoma) with β-hCG elevations only in a subset.

From a clinical biomarkers review (2024): - AFP is not elevated in pure seminoma; β-hCG can be mildly elevated in ~10–20% of pure seminoma cases (reviewed evidence). (sykes2024currentandevolving pages 2-4, sykes2024currentandevolving pages 1-2)

From an additional clinical overview source in the evidence set: - Pure seminomas usually have normal AFP, while β-hCG can be elevated when trophoblastic elements are present. (fazekas2024earlydetectionand pages 4-7)

3.2 Phenotype characteristics (onset, frequency, progression)

• Age range: commonly in young adult men; seminoma peak reported at 35–39 in one source. (fazekas2024earlydetectionand pages 4-7)
• Stage distribution: “nearly 80% of seminoma patients present with clinical stage I.” (sykes2024currentandevolving pages 2-4)
• Relapse risk after orchiectomy (stage I): generally 15–20% recurrence risk after orchiectomy, often within the first year. (sykes2024currentandevolving pages 4-5)

3.3 Suggested HPO terms (non-exhaustive, evidence-aligned)

Because the evidence set primarily addresses diagnosis/staging and biomarkers rather than symptom catalogs, HPO mapping here is conservative: - Testicular mass / testicular neoplasm phenotype concept (clinical presentation in evidence; no direct HPO IDs provided in sources). (sykes2024currentandevolving pages 4-5) - Abnormal serum β-hCG level (when elevated in seminoma subset). (fazekas2024earlydetectionand pages 10-13, sykes2024currentandevolving pages 2-4) - Abnormal serum LDH level. (fazekas2024earlydetectionand pages 10-13)

3.4 Quality-of-life impact

The evidence set emphasizes long-term toxicity/late effects as a major survivorship issue rather than QoL instrument scores.

4. Genetic / molecular information

4.1 Causal genes

Seminoma is not generally a single-gene Mendelian disorder; rather, it is a malignancy with recurrent somatic and copy-number alterations. In the accessible evidence: - KIT is repeatedly implicated (amplification in WGS cohort; mutations reported as seminoma-enriched in TGCT subtype analyses). (cabral2023somaticmutationdetection pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2)

4.2 Recurrent alterations and pathways (somatic/copy number)

12p copy-number gains (KRAS-region 12p): - WGS identified “chromosome arm-level gains spanning KRAS (12p)” among established recurrent CNAs. (leathlobhair2024genomiclandscapeof pages 1-2)

KIT focal amplification: - WGS found “amplifications involving KIT (4q12; 19% cases).” (leathlobhair2024genomiclandscapeof pages 1-2)

KRAS copy-number gain and prognosis (TGCT cohort): - In a 97-patient TGCT cohort, KRAS copy number gain occurred in 80.4% and was associated with worse 10-year OS (90% vs 81.5%, p=0.048). This is TGCT-wide and not seminoma-exclusive in the excerpt, but it is consistent with the prominence of 12p/KRAS-region alterations in TGCT biology. (cabral2023somaticmutationdetection pages 1-2)

4.3 Immune evasion / antigen presentation

HLA loss in seminoma: - WGS study: “human leukocyte antigen loss is a more prevalent mechanism of immune disruption in seminomas.” (leathlobhair2024genomiclandscapeof pages 1-2)

4.4 Epigenetic information

A 2023 review emphasizes that ncRNAs and epigenetic regulation are implicated in testicular cancers and that miRNA clusters (including 371–373) are candidates for liquid biopsy. (nunezcorona2023epigeneticfactorsand pages 2-3)

4.5 Suggested GO and CL terms (mechanism-aligned, non-exhaustive)

Based on evidence describing immune infiltration, exhaustion features, and developmental/primordial germ cell programs: - GO biological process (suggested): immune response modulation / antigen presentation processes (HLA loss context) (leathlobhair2024genomiclandscapeof pages 1-2) - CL cell types (suggested): CD4-positive T cell; regulatory T cell; follicular helper T cell; macrophage; dendritic cell (immune landscape evidence) (islam2024tcellsin pages 1-2)

5. Environmental information

The evidence set contains limited, seminoma-specific environmental exposure quantification. A 2024 epidemiologic review on cryptorchidism risk factors discusses maternal smoking and endocrine-disrupting chemical exposure as contributors to cryptorchidism risk, and cryptorchidism is associated with later testicular cancer risk, but causal environmental pathways to seminoma were not directly quantified in the evidence retrieved in this run. (OpenTargets Search: testicular seminoma)

6. Mechanism / pathophysiology

6.1 Causal chain (high-level, evidence-grounded)

1. Cell-of-origin / developmental arrest: seminoma reflects a germline developmental program resembling primordial germ cells and is considered GCNIS-derived. (lu2023singlecellmultiomicsanalysis pages 1-2)
2. Genomic evolution dominated by copy-number/structural changes: recurrent CNAs include 12p (KRAS-region) gains and KIT amplifications. (leathlobhair2024genomiclandscapeof pages 1-2)
3. Immune microenvironment and immune disruption: seminoma is characteristically immune-infiltrated; WGS suggests seminoma-enriched HLA loss as immune disruption; single-cell/spatial studies map immune subsets and exhaustion features near tumor. (islam2024tcellsin pages 1-2, lu2023singlecellmultiomicsanalysis pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2)
4. Clinical manifestations: testicular mass; early-stage predominance; marker-negative frequency for classic serum markers; excellent treatment sensitivity to radiotherapy and platinum chemotherapy. (fazekas2024earlydetectionand pages 10-13, sykes2024currentandevolving pages 4-5)

6.2 Immune system involvement (2023–2024 developments)

T-cell composition and rare subsets (2024): - Abstract quote: “Profound changes in immune cell composition within TGCT, shifting from macrophages in normal testes to T cells plus B and dendritic cells in TGCT, were documented. In most samples (96%), the CD4+ T cell frequency exceeded that of CD8+ cells… T cells including Treg and Tfh were most abundant in seminoma…” (islam2024tcellsin pages 1-2)

Single-cell/spatial multi-omics (2023): - Abstract quote: “We also identify 15 immune cell subtypes in TME, and find that subtypes with exhaustion features were located closer to the tumor region…” (lu2023singlecellmultiomicsanalysis pages 1-2)

7. Anatomical structures affected

• Primary organ: testis (seminoma is a testicular germ cell tumor). (lu2023singlecellmultiomicsanalysis pages 1-2)
• Metastatic pattern (general seminoma clinical pattern): predictable dissemination initially to the retroperitoneum before lungs/viscera is noted in a seminoma surgical management review (retrieved but not fully evidence-extracted in this run); therefore, detailed anatomic mapping is not citation-supported beyond general retroperitoneal involvement in the available sources. (thor2024mir371a3ppredictingviable pages 1-2)

Suggested UBERON terms (conceptual, evidence-aligned): testis; retroperitoneal lymph node region (metastatic/relapse surveillance contexts). (thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2)

8. Temporal development (natural history)

• Onset: typically young adulthood; seminoma described in men 14–44 and peak at 35–39 in the retrieved evidence. (fazekas2024earlydetectionand pages 4-7, lu2023singlecellmultiomicsanalysis pages 1-2)
• Stage at diagnosis: ~80% present with stage I (review evidence). (sykes2024currentandevolving pages 2-4)
• Relapse timing (stage I): relapses often within the first year after orchiectomy (review evidence). (sykes2024currentandevolving pages 4-5)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

From a 2024 clinical biomarkers review: - U.S. annual incidence: 5.7 per 100,000; 9,760 estimated new U.S. cases in 2024. (sykes2024currentandevolving pages 1-2)

9.2 Inheritance

No Mendelian inheritance model applies. Familial aggregation and susceptibility loci are widely recognized in the field, but GWAS-locus details (e.g., KITLG/DMRT1 variants) were not extractable with citation-grade support from the evidence gathered in this run.

10. Diagnostics

10.1 Conventional serum tumor markers (limitations)

Traditional serum tumor markers (AFP, β-hCG, LDH) are limited in seminoma. - Abstract quote (2024 review): “Traditional serum tumor markers … are limited by overall low sensitivity (approximately 50%)…” (sykes2024currentandevolving pages 1-2) - Seminoma-specific marker sensitivity reported in reviewed data: AFP 2.3%, β-hCG 31%, LDH 28%, and 46% combined. (sykes2024currentandevolving pages 1-2) - Additional clinically relevant proportions: β-hCG “15%–20% in advanced disease” and LDH “40%–60%” in seminoma patients (as summarized in one clinical overview source). (fazekas2024earlydetectionand pages 10-13)

10.2 Emerging liquid biomarkers — miR-371a-3p (M371)

Relapse detection in stage I surveillance (prospective, 2024): - Cohort: 258 stage I TGCT patients, median follow-up 18 months. - Relapse: 39 (15.1%) recurrences; “all with elevated M371 levels.” - Performance: AUC 0.993; sensitivity 100%; specificity 96.3%; PPV 83%; NPV 100%. - Earlier relapse detection: 28%, but without significant median time gain.

Primary abstract quote: - “Thirty-nine patients recurred (15.1%), all with elevated M371 levels… area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%.” (belge2024detectionofrecurrence pages 1-2)

Viable tumor detection around RPLND (prospective, 2024): - In primary seminoma patients (n=24) undergoing primary RPLND, miR-371a-3p sensitivity 74% and specificity 100% (threshold >0.45 copies/µL), with decreased levels after surgery. (thor2024mir371a3ppredictingviable pages 1-2)

10.3 Imaging

For post-chemotherapy residual masses in seminoma, PET-CT is described as having high negative predictive value for masses >3 cm but low positive predictive value due to false positives. (sykes2024currentandevolving pages 4-5)

10.4 Pathology (histopathology/IHC)

Seminoma is described morphologically as immune-infiltrated and PGC-like in gene expression programs. - Gene-expression diagnostic markers: TFAP2C, SOX17, POU5F1/OCT4, NANOG are described as highly expressed and noted as “excellent diagnostic markers for seminoma and GCNIS.” (lu2023singlecellmultiomicsanalysis pages 1-2)

10.5 Differential diagnosis

The retrieved evidence does not provide a comprehensive differential diagnosis table (e.g., embryonal carcinoma, lymphoma, spermatocytic tumor) in extractable form.

11. Outcome / prognosis

• TGCT prognosis is generally favorable: survival “approaching 99%” for early-stage disease and “exceeding 80%” for advanced-stage disease (review statement). (sykes2024currentandevolving pages 1-2)
• A retrospective surveillance cohort cited in the biomarkers review reported 5-year survival 99% (stage I management context). (sykes2024currentandevolving pages 4-5)
• A clinical overview states that “With current standard-of-care management 90–95% of testicular tumors are cured.” (fazekas2024earlydetectionand pages 10-13)

12. Treatment

12.1 Standard-of-care management (real-world implementation)

Stage I seminoma: - Radical orchiectomy is the foundational diagnostic/therapeutic step; post-orchiectomy options include surveillance (preferred), single-agent carboplatin (1–2 cycles), or radiotherapy. (sykes2024currentandevolving pages 4-5)

Rationale for surveillance/de-escalation: - A large fraction of stage I seminoma patients do not relapse; consequently, management aims to limit long-term toxicities in a young survivorship population. (sykes2024currentandevolving pages 4-5, sykes2024currentandevolving pages 1-2)

12.2 Long-term toxicities (key survivorship issue)

A 2024 review highlights long-term risks with radiation/chemotherapy; in the extracted evidence, radiation is associated with an “80% increased risk of death from secondary malignancy” (as presented in the review excerpt). (sykes2024currentandevolving pages 4-5)

12.3 Suggested MAXO terms (conceptual placeholders)

The evidence does not include MAXO IDs, but supports the following action concepts: - Radical inguinal orchiectomy; active surveillance; radiotherapy; platinum-based chemotherapy; retroperitoneal lymph node dissection (in selected contexts). (sykes2024currentandevolving pages 4-5, thor2024mir371a3ppredictingviable pages 1-2)

13. Prevention

No primary prevention interventions with evidence-supported efficacy were retrieved. Secondary prevention in practice is primarily risk-adapted surveillance and follow-up after orchiectomy. (sykes2024currentandevolving pages 4-5, belge2024detectionofrecurrence pages 1-2)

14. Other species / natural disease

No cross-species naturally occurring seminoma evidence was retrieved in the citation-grade set for this run.

15. Model organisms

The evidence set includes in vitro functional work referenced in a single-cell/multi-omics study (seminoma cell line usage), but detailed model organism cataloging was not extracted. (lu2023singlecellmultiomicsanalysis pages 1-2)

16. Recent developments & expert synthesis (2023–2024)

16.1 Genomics (2024 WGS at scale)

The Genomics England 100,000 Genomes Project WGS analysis provides a “high-resolution map” of CNAs/SVs and reports seminoma-enriched HLA loss as an immune-disruption mechanism, supporting immune-evasion hypotheses and potentially informing immunotherapy biomarker strategy. (leathlobhair2024genomiclandscapeof pages 1-2)

16.2 Tumor microenvironment atlases (2023–2024)

Single-cell/spatial profiling identifies immune heterogeneity, including exhaustion-featured immune states near tumor, and Br J Cancer 2024 highlights CD4-predominant infiltration and seminoma enrichment for rare Treg/Tfh subsets—collectively supporting a view of seminoma as an immune-infiltrated but potentially immunoregulatory/exhausted environment. (islam2024tcellsin pages 1-2, lu2023singlecellmultiomicsanalysis pages 1-2)

16.3 Liquid biopsy (miR-371a-3p) nearing implementation

Prospective validation shows M371’s high accuracy for relapse detection in stage I surveillance and high specificity in certain contexts (e.g., seminoma pre-chemotherapy RPLND cohort). Expert review consensus frames miR-371a-3p as a leading candidate biomarker with ~90–92% sensitivity and ~84–86% specificity overall in GCT patients, while noting limitations such as inability to detect teratoma. (thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2, sykes2024currentandevolving pages 1-2)

16.4 Ongoing trials / studies

A recruiting observational study to evaluate miRNA371 and outcomes in newly diagnosed germ cell tumors is identified as NCT07453082 (enrollment 100). (sykes2024currentandevolving pages 8-10)

Evidence summary table

The following table consolidates the key evidence-backed facts extracted in this run.

Table: This table condenses the strongest evidence gathered on testicular seminoma across definition, epidemiology, biology, diagnostics, treatment, and active trials. It is designed as a quick-reference artifact using only facts supported by the cited context IDs.

Key limitations of this report (evidence availability constraints)

1. Ontology identifiers (ICD, MeSH, Orphanet, OMIM, MONDO for seminoma) were not available in the retrieved citation-grade evidence. Only a broader TGCT MONDO term appeared in OpenTargets output. (OpenTargets Search: testicular seminoma)
2. Seminoma-specific environmental risk quantification (beyond association framing and the NDD OR from one study) was limited in the gathered evidence. (OpenTargets Search: testicular seminoma)
3. GWAS susceptibility loci and germline variant details were not extractable with citation support from the texts retrieved in this run.

References (URLs and publication dates)

• Lu X et al. Nature Communications (Accepted 2023-12-07; DOI page indicates 2023 publication). https://doi.org/10.1038/s41467-023-44305-9 (lu2023singlecellmultiomicsanalysis pages 1-2)
• Ní Leathlobhair M et al. Nature Communications (Accepted 2024-10-03). https://doi.org/10.1038/s41467-024-53193-6 (leathlobhair2024genomiclandscapeof pages 1-2)
• Islam R et al. British Journal of Cancer (Published online 2024-04-22). https://doi.org/10.1038/s41416-024-02669-9 (islam2024tcellsin pages 1-2)
• Belge G et al. Clinical Cancer Research (2024-11; DOI). https://doi.org/10.1158/1078-0432.CCR-23-0730 (belge2024detectionofrecurrence pages 1-2)
• Thor A et al. Journal of Urology (2024-11; DOI). https://doi.org/10.1097/JU.0000000000004164 (thor2024mir371a3ppredictingviable pages 1-2)
• Sykes J et al. Journal of Clinical Medicine (Published 2024-12-06). https://doi.org/10.3390/jcm13237448 (sykes2024currentandevolving pages 1-2)
• Fazekas F. ArXiv / thesis deposit (2024; DOI). https://doi.org/10.14232/phd.12359 (fazekas2024earlydetectionand pages 4-7)
• Cabral ERM et al. Frontiers in Oncology (2023-03; DOI). https://doi.org/10.3389/fonc.2023.1133363 (cabral2023somaticmutationdetection pages 1-2)

References

1. (leathlobhair2024genomiclandscapeof pages 1-2): Máire Ní Leathlobhair, A. Frangou, B. Kinnersley, A. Cornish, D. Chubb, E. Lakatos, P. Arumugam, Andreas J. Gruber, P. Law, Avraam Tapinos, G. M. Jakobsdottir, I. Peneva, A. Sahli, Evie M Smyth, R. Ball, R. Sylva, K. Benes, D. Stark, Robin J Young, Alexander T J Lee, Vincent Wolverson, R. Houlston, A. Sosinsky, A. Protheroe, Matthew J. Murray, D. Wedge, C. Verrill, and Máire Anna Ben Alex J. Daniel Richard Y. Rushan Ksenija Ní Leathlobhair Frangou Kinnersley Cornish Chubb B. Genomic landscape of adult testicular germ cell tumours in the 100,000 genomes project. Nature Communications, Oct 2024. URL: https://doi.org/10.1038/s41467-024-53193-6, doi:10.1038/s41467-024-53193-6. This article has 17 citations and is from a highest quality peer-reviewed journal.

2. (thor2024mir371a3ppredictingviable pages 1-2): Anna Thor, Mette Pernille Myklebust, Anna Grenabo Bergdahl, Per-Olof Lundgren, Viktor Skokic, Bjarte Almås, Hege Sagstuen Haugnes, Torgrim Tandstad, Olof Akre, Gabriella Cohn-Cedermark, Olav Dahl, and Anders Kjellman. Mir-371a-3p predicting viable tumor in patients undergoing retroperitoneal lymph node dissection for metastatic testicular cancer: the swenoteca-mir study. Nov 2024. URL: https://doi.org/10.1097/ju.0000000000004164, doi:10.1097/ju.0000000000004164. This article has 9 citations and is from a domain leading peer-reviewed journal.

3. (islam2024tcellsin pages 1-2): Rashidul Islam, Jannis Heyer, Miriam Figura, Xiaoyan Wang, Xichen Nie, Benedict Nathaniel, Sivanjah Indumathy, Katja Hartmann, Christiane Pleuger, Monika Fijak, Sabine Kliesch, Florian Dittmar, Adrian Pilatz, Florian Wagenlehner, Mark Hedger, Bruce Loveland, James H. Hotaling, Jingtao Guo, Kate Loveland, Hans-Christian Schuppe, and Daniela Fietz. T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets. British Journal of Cancer, 130:1893-1903, Sep 2024. URL: https://doi.org/10.1038/s41416-024-02669-9, doi:10.1038/s41416-024-02669-9. This article has 22 citations and is from a domain leading peer-reviewed journal.

4. (belge2024detectionofrecurrence pages 1-2): Gazanfer Belge, Cansu Dumlupinar, Tim Nestler, Markus Klemke, Peter Törzsök, Emanuela Trenti, Renate Pichler, Wolfgang Loidl, Yue Che, Andreas Hiester, Cord Matthies, Martin Pichler, Pia Paffenholz, Luis Kluth, Mike Wenzel, Jörg Sommer, Julia Heinzelbecker, Philipp Schriefer, Alexander Winter, Friedemann Zengerling, Mario Wolfgang Kramer, Marie Lengert, Jana Frey, Axel Heidenreich, Christian Wülfing, Arlo Radtke, and Klaus-Peter Dieckmann. Detection of recurrence through microrna-371a-3p serum levels in a follow-up of stage i testicular germ cell tumors in the drks-00019223 study. Clinical Cancer Research, 30:404-412, Nov 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-0730, doi:10.1158/1078-0432.ccr-23-0730. This article has 37 citations and is from a highest quality peer-reviewed journal.

5. (lu2023singlecellmultiomicsanalysis pages 1-2): Xiaojian Lu, Yanwei Luo, Xichen Nie, Bailing Zhang, Xiaoyan Wang, Ran Li, Guangmin Liu, Qianyin Zhou, Zhizhong Liu, Liqing Fan, James M. Hotaling, Zhe Zhang, Hao Bo, and Jingtao Guo. Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-44305-9, doi:10.1038/s41467-023-44305-9. This article has 37 citations and is from a highest quality peer-reviewed journal.

6. (sykes2024currentandevolving pages 1-2): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.

7. (OpenTargets Search: testicular seminoma): Open Targets Query (testicular seminoma, 31 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (fazekas2024earlydetectionand pages 4-7): Fruzsina Fazekas. Early detection and complex treatment of metastatic testicular germ cell cancer. ArXiv, 2024. URL: https://doi.org/10.14232/phd.12359, doi:10.14232/phd.12359. This article has 1 citations.

9. (sykes2024currentandevolving pages 2-4): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.

10. (sykes2024currentandevolving pages 4-5): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.

11. (fazekas2024earlydetectionand pages 10-13): Fruzsina Fazekas. Early detection and complex treatment of metastatic testicular germ cell cancer. ArXiv, 2024. URL: https://doi.org/10.14232/phd.12359, doi:10.14232/phd.12359. This article has 1 citations.

12. (cabral2023somaticmutationdetection pages 1-2): Eduardo R. M. Cabral, Marilia F. Pacanhella, Andre V. H. Lengert, Mariana B. dos Reis, Leticia F. Leal, Marcos A. de Lima, Aline L. V. da Silva, Icaro A. Pinto, Rui M. Reis, Mariana T. Pinto, and Flavio M. Cárcano. Somatic mutation detection and kras amplification in testicular germ cell tumors. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1133363, doi:10.3389/fonc.2023.1133363. This article has 12 citations.

13. (nunezcorona2023epigeneticfactorsand pages 2-3): David Nuñez-Corona, Estefania Contreras-Sanzón, Jonathan Puente-Rivera, Rodrigo Arreola, Minerva Camacho-Nuez, José Cruz Santiago, Edgar Antonio Estrella-Parra, Julio César Torres-Romero, César López-Camarillo, and María Elizbeth Alvarez-Sánchez. Epigenetic factors and ncrnas in testicular cancer. International Journal of Molecular Sciences, 24:12194, Jul 2023. URL: https://doi.org/10.3390/ijms241512194, doi:10.3390/ijms241512194. This article has 14 citations.

14. (sykes2024currentandevolving pages 8-10): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.

Artifacts

• Edison artifact artifact-00